Celcuity, Inc. (NASDAQ:CELC) Given Consensus Rating of “Moderate Buy” by Brokerages

Celcuity, Inc. (NASDAQ:CELC) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $154.5455.

Several brokerages have recently issued reports on CELC. Leerink Partners set a $155.00 price target on Celcuity in a research note on Tuesday, June 2nd. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Wells Fargo & Company dropped their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Stifel Nicolaus cut their target price on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a research note on Monday.

Hedge Funds Weigh In On Celcuity

Several large investors have recently bought and sold shares of CELC. Creative Planning bought a new position in Celcuity in the second quarter valued at approximately $177,000. Rhumbline Advisers raised its position in shares of Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after acquiring an additional 503 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Celcuity in the 2nd quarter valued at $169,000. Quantinno Capital Management LP lifted its stake in shares of Celcuity by 20.7% in the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after purchasing an additional 41,756 shares during the period. Finally, Paloma Partners Management Co lifted its stake in shares of Celcuity by 285.8% in the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after purchasing an additional 60,849 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Price Performance

CELC opened at $93.64 on Thursday. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The stock has a market capitalization of $4.58 billion, a P/E ratio of -21.78 and a beta of 0.20. The company’s 50 day simple moving average is $94.10 and its 200-day simple moving average is $107.95. Celcuity has a one year low of $44.42 and a one year high of $151.02.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Sell-side analysts anticipate that Celcuity will post -4.51 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.